Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder of the colon with a variable clinical course of exacerbation and remission. Extraintestinal manifestations of UC, including hematological disorders, such as the rare immune thrombocytopenic purpura (ITP), may be the presenting symptoms. We encountered the case of a 23-year-old man with UC who showed typical symptoms and endoscopic findings. Despite receiving steroid treatment, the patient developed severe thrombocytopenia. He was diagnosed with ITP, characterized by autoimmunity, a demonstrated low platelet count, normal bone marrow, positivity for autoantibody to platelet membrane antigen, and no splenomegaly. We initiated high dose intravenous immunoglobulin immediately for treatment of his steroid-refractory thrombocytopenia. The patient's hematochezia and platelet count improved following immunoglobulin treatment. After discharge, the patient's platelet count was maintained at a stable level and his condition was good. This case suggests that immunoglobulin therapy may be useful for treatment of ITP in UC. (Korean J Gastroenterol 2014;64:234-238) 
INTRODUCTION
Ulcerative colitis (UC) is a type of chronic inflammatory bowel disease of unknown etiology that affects the entire colon and is characterized by a lack of inflammation in the deeper layers of the colonic wall. 1 Immune thrombocytopenic purpura (ITP) is characterized by low platelet counts resulting from both immune-mediated platelet destruction and suppression of platelet production, which are caused by autoantibodies against platelet membrane antigens. 2 Several reports have described cases of UC associated with extraintestinal symptoms in Korea; however, coexistence of UC and ITP is rare. Previous reports have described the occur-rence of ITP in patients with UC and hypothesized that it represents an immunologically mediated extraintestinal manifestation similar to mucocutaneous lesions, hepatobiliary disease, arthropathy, and hematological disorders. 1, [3] [4] [5] [6] Enhanced exposure to luminal antigens has been suggested as a cause of immune-mediated thrombocytopenia due to the increased mucosal permeability observed in UC patients. 6, 7 Few cases of ITP in patients with UC have been reported; as a result, treatment has not yet been clearly established. In the current report, we describe a case of ITP in a patient with UC and discuss causal relationship between the two diseases. 
CASE REPORT
In August 2013, a 23-year-old man presented with a two-week history of bloody diarrhea. He had visited a local hospital and was diagnosed with UC of the pancolitis type, based on the clinical features and colonoscopy findings.
Treatment with oral prednisolone (40 mg/day) and 5-aminosalicylic acid (5-ASA) was initiated, but was unsuccessful.
After treatment for two weeks, the patient was transferred to our hospital for further treatment. He had no medical or fam- However, the results were not remarkable, with the exception of a positive result on an anti-platelet antibody test.
After consulting a hematologist, we performed bone marrow aspiration on day 10, which indicated a normocellular marrow with a normal number of megakaryocytes and normal morphology (Fig. 3) .
Thus, the patient was diagnosed with ITP in addition to UC according to the criteria established by the International Working Group for ITP. 8 He had no history of autoimmune or immunodeficiency disorders, liver disease, use of drugs for thrombocytopenia, or inherited thrombocytopenia. Based on the laboratory data, other causes of secondary thrombocytopenia, including viral infections, disseminated intravascular coagulation, hemolytic uremic syndrome, and lymphoproliferative disorders were excluded. In recent years, several studies have proposed a possible association of Helicobacter pylori infection with ITP. [9] [10] [11] We performed endoscopy and a rapid urease test; H. pylori infection was not detected.
Therefore, we did not perform H. pylori eradication.
Due to a lack of response to steroids, 1 g/kg of immunoglobulins was administered intravenously on two consecutive days (days 16 and 17). After this infusion, the patient's symptoms improved and the number of platelets increased from 17,000/L to 65,000/L (Fig. 4 ). Therefore, we switched his medication to 40 mg of oral steroids, and then gradually reduced the steroid dose by 5 mg every week.
The patient was discharged on day 22, and his serum platelet count had recovered to 98,000/L on day 21 after discharge. Subsequently, at three months after discharge, colonoscopic findings ( Fig. 5 ) and CRP, ESR levels showed mucosal healing and normal levels, respectively.
DISCUSSION
Since Edwards and Truelove 12 originally described three patients with both ITP and UC in 1964, few cases of the coexistence of ITP and UC have been reported. UC may be concomitant with hematological disorders such as iron deficiency anemia due to colon bleeding, megaloblastic anemia caused by malabsorption of vitamin B12 or folic acid, and autoimmune hemolytic anemia. 13, 14 However, although the number of reported cases has recently increased, no definitive correlation between UC and ITP has been proposed.
ITP is presumed to be related to the destruction of antibody-coated platelets by macrophages and suppression of megakaryocytopoiesis via production of specific IgG autoantibodies from the patient's B cells. 13 In UC patients with ITP, one proposed hypothesis is that the increased permeability and translocation of antibodies to luminal bacterial antigens by bowel inflammation might lead to platelet antibody formation through cross reactivity. 6 ITP occurs during the active stage of UC, which is characterized by extensive and significant colonic inflammation, leading to degradation of platelet glycoproteins and subsequent antibody formation. 6 Approximately half of affected patients with both diseases respond well to steroid treatment. However, in other cases, surgery such as splenectomy or colectomy is required. 3, 4 In the current case, we administered steroid therapy for management of UC, which could also serve as a treatment for ITP. 15, 16 However, the thrombocytopenia did not improve.
Therefore, we utilized other treatment options, including immunoglobulin therapy. The increase in platelet count, which can be expected to persist for approximately one week following immunoglobulin infusion, 14 usually occurs on the 2nd-3rd day after initiation of immunoglobulin treatment. Intravenous immunoglobulin is used to manage internal bleeding when the platelet count remains very low even after several days of corticosteroid treatment. 13 The mechanism of action of immunoglobulin is presumed to involve the temporary interference with the function of the mononuclear phagocyte system Fc receptor. 17 This treatment is known to be effective in approximately 80% of patients, although it does not frequently result in sustained remission. 18 In the current case, In the current case, UC with ITP, which was refractory to medical treatment with high-dose prednisolone, responded to rescue therapy with immunoglobulin. Thus, we avoided the need for surgical treatment such as splenectomy or colectomy. In conclusion, although immunoglobulin therapy is known to be effective for only a short duration, we suggest that immunoglobulin therapy may be useful for treatment of UC-related ITP that is refractory to steroids and can therefore be helpful in avoiding the need for surgery.
